RYALTRIS Drug Patent Profile
✉ Email this page to a colleague
When do Ryaltris patents expire, and when can generic versions of Ryaltris launch?
Ryaltris is a drug marketed by Glenmark Specialty and is included in one NDA. There are fourteen patents protecting this drug.
This drug has eighty-eight patent family members in thirty-two countries.
The generic ingredient in RYALTRIS is mometasone furoate; olopatadine hydrochloride. There are thirty drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the mometasone furoate; olopatadine hydrochloride profile page.
DrugPatentWatch® Generic Entry Outlook for Ryaltris
By analyzing the patents and regulatory protections it appears that the earliest date
for generic entry will be January 13, 2025. This may change due to patent challenges or generic licensing.
Indicators of Generic Entry
Summary for RYALTRIS
International Patents: | 88 |
US Patents: | 14 |
Applicants: | 1 |
NDAs: | 1 |
Finished Product Suppliers / Packagers: | 1 |
Formulation / Manufacturing: | see details |
Drug Prices: | Drug price information for RYALTRIS |
What excipients (inactive ingredients) are in RYALTRIS? | RYALTRIS excipients list |
DailyMed Link: | RYALTRIS at DailyMed |
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for RYALTRIS
Generic Entry Date for RYALTRIS*:
Constraining patent/regulatory exclusivity:
NEW PRODUCT NDA:
Dosage:
SPRAY, METERED;NASAL |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Pharmacology for RYALTRIS
Drug Class | Corticosteroid Histamine-1 Receptor Antagonist Histamine-1 Receptor Inhibitor Mast Cell Stabilizer |
Mechanism of Action | Corticosteroid Hormone Receptor Agonists Histamine H1 Receptor Antagonists |
Physiological Effect | Decreased Histamine Release |
Anatomical Therapeutic Chemical (ATC) Classes for RYALTRIS
US Patents and Regulatory Information for RYALTRIS
RYALTRIS is protected by fourteen US patents and one FDA Regulatory Exclusivity.
Based on analysis by DrugPatentWatch, the earliest date for a generic version of RYALTRIS is ⤷ Try a Trial.
This potential generic entry date is based on NEW PRODUCT.
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
Patents protecting RYALTRIS
Treatment of allergic rhinitis using a combination of mometasone and olopatadine
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: TREATMENT OF SEASONAL ALLERGIC RHINITIS BY NASALY ADMINISTERING A COMBINATION OF OLOPATADINE HYDROCHLORIDE AND MOMETASONE FUROATE
Stable fixed dose pharmaceutical composition comprising mometasone and olopatadine
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Stable fixed dose pharmaceutical composition comprising mometasone and olopatadine
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: TREATMENT OF SEASONAL ALLERGIC RHINITIS BY NASALY ADMINISTERING A COMBINATION OF OLOPATADINE HYDROCHLORIDE AND MOMETASONE FUROATE
Treatment of allergic rhinitis using a combination of mometasone and olopatadine
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: TREATMENT OF SEASONAL ALLERGIC RHINITIS BY NASALY ADMINISTERING A COMBINATION OF OLOPATADINE HYDROCHLORIDE AND MOMETASONE FUROATE
Stable fixed dose pharmaceutical composition comprising mometasone and olopatadine
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Treatment of allergic rhinitis using a combination of mometasone and olopatadine
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: TREATMENT OF SEASONAL ALLERGIC RHINITIS BY NASALY ADMINISTERING A COMBINATION OF OLOPATADINE HYDROCHLORIDE AND MOMETASONE FUROATE
Treatment of allergic rhinitis using a combination of mometasone and olopatadine
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: TREATMENT OF SEASONAL ALLERGIC RHINITIS BY NASALY ADMINISTERING A COMBINATION OF OLOPATADINE HYDROCHLORIDE AND MOMETASONE FUROATE TO A PEDIATRIC PATIENT
Stable fixed dose pharmaceutical composition comprising mometasone and olopatadine
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: METHOD OF DELIVERING A COMBINATION OF OLOPATADINE HYDROCHLORIDE AND MOMETASONE FUROATE TO A NASAL AIRWAY
Treatment of allergic rhinitis using a combination of mometasone and olopatadine
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: TREATMENT OF SEASONAL ALLERGIC RHINITIS BY NASALY ADMINISTERING A COMBINATION OF OLOPATADINE HYDROCHLORIDE AND MOMETASONE FUROATE
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Stable fixed dose pharmaceutical composition comprising mometasone and olopatadine
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: TREATMENT OF SEASONAL ALLERGIC RHINITIS BY NASALY ADMINISTERING A COMBINATION OF OLOPATADINE HYDROCHLORIDE AND MOMETASONE FUROATE
Stable fixed dose pharmaceutical composition comprising mometasone and olopatadine
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Stable fixed dose pharmaceutical composition comprising mometasone and olopatadine
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: TREATMENT OF SEASONAL ALLERGIC RHINITIS BY NASALY ADMINISTERING A COMBINATION OF OLOPATADINE HYDROCHLORIDE AND MOMETASONE FUROATE
Stable fixed dose pharmaceutical composition comprising mometasone and olopatadine
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
FDA Regulatory Exclusivity protecting RYALTRIS
NEW PRODUCT
Exclusivity Expiration: ⤷ Try a Trial
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Glenmark Specialty | RYALTRIS | mometasone furoate; olopatadine hydrochloride | SPRAY, METERED;NASAL | 211746-001 | Jan 13, 2022 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Glenmark Specialty | RYALTRIS | mometasone furoate; olopatadine hydrochloride | SPRAY, METERED;NASAL | 211746-001 | Jan 13, 2022 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
Glenmark Specialty | RYALTRIS | mometasone furoate; olopatadine hydrochloride | SPRAY, METERED;NASAL | 211746-001 | Jan 13, 2022 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for RYALTRIS
See the table below for patents covering RYALTRIS around the world.
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
South Korea | 20200125625 | 모메타손 및 올로파타딘의 조합을 사용하는 소아 대상체의 알레르기성 비염의 치료 | ⤷ Try a Trial |
Mexico | 2020008741 | TRATAMIENTO DE LA RINITIS ALERGICA EN SUJETOS PEDIATRICOS CON UNA COMBINACION DE MOMETASONA Y OLOPATADINA. (TREATMENT OF ALLERGIC RHINITIS IN PEDIATRIC SUBJECTS USING A COMBINATION OF MOMETASONE AND OLOPATADINE.) | ⤷ Try a Trial |
Russian Federation | 2015128497 | СТАБИЛЬНАЯ ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ С ФИКСИРОВАННОЙ ДОЗОЙ, СОДЕРЖАЩАЯ МОМЕТАЗОН И ОЛОПАТАДИН | ⤷ Try a Trial |
>Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for RYALTRIS
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
3043773 | 2021045 | Norway | ⤷ Try a Trial | PRODUCT NAME: MOMETASON ELLER ET SALT DERAV OG OLOPATADIN ELLER ET SALT DERAV; NAT. REG. NO/DATE: 20-13278 20210709; FIRST REG. NO/DATE: 140638 20210426 |
3043773 | 122021000085 | Germany | ⤷ Try a Trial | PRODUCT NAME: MOMETASON ODER EIN SALZ DAVON UND OLOPATADIN ODER EIN SALZ DAVON; NAT. REGISTRATION NO/DATE: 2205824.00.00 20211117; FIRST REGISTRATION: OESTERREICH 140638 20210426 |
0112669 | 96C0002 | Belgium | ⤷ Try a Trial | PRODUCT NAME: MOMETASONE FUROATE; NAT. REGISTRATION NO/DATE: NL 19601 19950919; FIRST REGISTRATION: GR - 10681/89 19900622 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |